Command Palette

Search for a command to run...

Aspira Pathlab&Diagn
60.32(-1.07%)
1W: -2.74%

Aspira Pathlab&Diagn Peer Comparison

Snapshot Summary

Aspira Pathlab & Diagnostics Ltd. is significantly underperforming compared to its peers across various financial metrics, showing no growth, no profitability, and high valuation ratios, making it a laggard in the Hospital & Healthcare Services sector.

  • • Aspira shows zero growth in revenue and EPS across periods.
  • • All profitability metrics (ROE, ROA, ROCE) are absent for Aspira, indicating no returns.
  • • Compared to peers, Aspira's PE and PBV ratios are high without corresponding profitability.
  • • Max Healthcare Institute Ltd.: Highest revenue growth YoY (18.49%) and strong profitability with a ROE of 13.47%.
  • • Narayana Hrudayalaya Ltd.: Strong ROE of 24.27%, good revenue growth, and attractive PE ratio.
  • • Global Health Ltd.: Solid revenue growth YoY (21.56%) and a favorable debt-to-equity ratio (0.0968).
Stock
CMP
Market Cap
P/E
ROE (%)
ROCE (%)
Debt/Equity
Aspira Pathlab & Diagnostics Ltd.₹60.97-0.00---
APOLLOHOSP₹7,824.50₹1,12,510.06Cr71.5020.51%21.19%0.67
MAXHEALTH₹1,145.90₹1,11,466.91Cr97.1313.47%16.26%0.14
FORTIS₹1,030.70₹77,269.97Cr88.979.77%12.14%0.25
NH₹1,785.00₹36,492.71Cr46.4624.27%21.62%0.61
ASTERDM₹678.45₹35,159.69Cr110.519.32%11.46%0.19
MEDANTA₹1,274.60₹34,290.93Cr64.2015.31%20.50%0.10

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.

Explore
Watchlists